Drug intelligence / Profile preview

Artynerv

Development stage: Unknown
Lead developer: Jointherapeutics
Modality: Small Molecules
Administration: Oral

Overview

Artynerv is a nutraceutical food supplement developed by Jointherapeutics, specifically formulated to support the health of the central and peripheral nervous systems as well as articular and vertebral joints. The formulation combines several key ingredients: a vitamin B complex, which is essential for nerve metabolism and the maintenance of the myelin sheath; omega-3 fatty acids, known for their anti-inflammatory properties; and glucosamine and chondroitin, which serve as structural components for cartilage repair and joint integrity. Additionally, it contains *Piper nigrum* extract (piperine) to enhance the bioavailability of the other components. Artynerv is intended for individuals seeking to maintain or improve joint mobility and nerve function through nutritional supplementation.

Brand names: Artynerv

Beyond the preview

Go deeper on Artynerv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Artynerv.

Explore the full profile